An update from the phase 2 LEGEND trial shows that the investigational nonviral gene therapy detalimogene voraplasmid has achieved a 62% complete response rate at six months in patients with high-risk ...

The number and frequency of intravesical instillations for non-muscle-invasive bladder cancer (NMIBC) impairs quality of life and needs to be reported in clinical trials.

A research team at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) has developed a radiopharmaceutical molecule marker that ...

CHAD Thompson grappled with a silent problem for 20 years – he couldn’t pee properly, and it was a constant source of anxiety ...

Increases in variant histology bladder cancer in the US highlight the importance of precision in pathologic review of biopsy specimens. The diagnosis of variant histology bladder cancers is increasing ...

Engineering oncolytic adenoviruses (OAds) to treat renal and bladder cancers has advanced rapidly. Leveraging insights into adenovirus biology, the molecular pathology of cancer, and recent progress ...

Scientists uncovered how childhood BK virus infections may set off cancer-causing mutations decades later: by activating a host immune system enzyme that attacks DNA. When you purchase through links ...

Tackling a common childhood virus could open the door to preventing bladder cancer, according to new research funded by Kidney Research UK and York Against Cancer. The study, published in Science ...

When Tim Tavender developed a common virus, he had no idea it was the start of what would later become a cancer diagnosis. The 51-year-old from Southampton became ill with BK virus, also known as ...

Tackling a common childhood virus could open the door to preventing bladder cancer, according to new research. The study, published in Science Advances by Dr. Simon Baker and colleagues at the ...

Tackling a common childhood virus could open the door to preventing bladder cancer, according to new research funded by Kidney Research UK and York Against Cancer. The study, published in Science ...

The FDA has approved Pfizer and Astellas’ Padcev (enfortumab vedotin-ejfv) plus Merck’s Keytruda (pembrolizumab) as a perioperative treatment for adults with muscle-invasive bladder cancer who are ...